本文選題：丹參注射液 + 尼莫地平緩釋片　； 參考：《中國臨床藥理學(xué)雜志》2017年08期

【摘要】：目的觀察丹參注射液聯(lián)合尼莫地平緩釋片治療高血壓出血性腦卒中的臨床療效及安全性。方法將106例新發(fā)高血壓出血性腦卒中患者分為對(duì)照組64例和試驗(yàn)組42例。對(duì)照組予以吸氧、吸痰、控制腦水腫、維持電解質(zhì)平衡、營養(yǎng)腦細(xì)胞等常規(guī)治療;試驗(yàn)組在對(duì)照組治療的基礎(chǔ)上,予以丹參注射液10 mg·d~(-1),靜脈滴注速度1 mg·h~(-1)+尼莫地平緩釋片每次20 mg,tid,口服。2組患者均治療14 d。比較2組患者的臨床療效、血腫吸收情況,以及藥物不良反應(yīng)的發(fā)生情況。結(jié)果治療后,試驗(yàn)組和對(duì)照組的總有效率分別為95.24%(40/42例)和85.94%(55/64例),差異有統(tǒng)計(jì)學(xué)意義(P0.05)。治療后第14,28天,試驗(yàn)組的平均血腫體積分別為(8.26±4.39),(6.76±3.16)mL,對(duì)照組的平均血腫體積分別為(12.41±5.02),(9.33±4.78)mL,差異均有統(tǒng)計(jì)學(xué)意義(均P0.05)。試驗(yàn)組的藥物不良反應(yīng)主要有頭痛、胃腸道反應(yīng)、低血壓、血小板減少、皮膚刺痛,對(duì)照組的藥物不良反應(yīng)主要有頭痛、胃腸道反應(yīng)。試驗(yàn)組和對(duì)照組的藥物不良反應(yīng)發(fā)生率分別為19.04%(8/42例)和7.81%(5/64例),差異無統(tǒng)計(jì)學(xué)意義(P0.05)。結(jié)論丹參注射液聯(lián)合尼莫地平緩釋片治療高血壓出血性腦卒中的臨床療效肯定,能顯著地促進(jìn)血腫的吸收,且不增加藥物不良反應(yīng)的發(fā)生率。
[Abstract]:Objective to observe the efficacy and safety of salvia miltiorrhiza injection combined with nimodipine sustained-release tablet in the treatment of hypertensive hemorrhagic stroke. Methods 106 patients with newly developed hypertensive hemorrhagic stroke were divided into control group (n = 64) and experimental group (n = 42). The control group received routine treatment such as oxygen inhalation, sputum suction, brain edema control, electrolyte balance, nutrition brain cells, etc. The experimental group was treated on the basis of the control group. Salvia miltiorrhiza injection (10 mg / d) was given intravenously at a rate of 1 mg / h ~ (-1) nimodipine sustained release tablet (20 mg / d) for 14 days. The clinical efficacy, hematoma absorption and adverse drug reactions were compared between the two groups. Results after treatment, the total effective rates of the test group and the control group were 95.2440 / 42 and 85.94, 55 / 64, respectively. The difference was statistically significant (P 0.05). On the 28th day after treatment, the mean hematoma volume in the experimental group was 6.76 鹵3.16mL, and the mean hematoma volume in the control group was 12.41 鹵5.02 鹵4.78mL, respectively. The difference was statistically significant (all P 0.05). The main adverse drug reactions in the trial group were headache, gastrointestinal reaction, hypotension, thrombocytopenia, prickly skin, and the main adverse drug reactions in the control group were headache and gastrointestinal reaction. The incidence of adverse drug reactions in the test group and the control group were 19.04 / 42 and 7.81 / 5 / 64, respectively. There was no significant difference between the two groups in the incidence of adverse drug reactions (P 0.05). Conclusion Salvia miltiorrhiza injection combined with nimodipine sustained-release tablet is effective in the treatment of hypertensive hemorrhagic stroke. It can significantly promote the absorption of hematoma and does not increase the incidence of adverse drug reactions.
【作者單位】： �？谑腥嗣襻t(yī)院神經(jīng)內(nèi)科;海南省農(nóng)墾總局醫(yī)院神經(jīng)內(nèi)科;
【基金】：海南省自然科學(xué)基金資助項(xiàng)目(30716)
【分類號(hào)】：R544.1;R743.3

【相似文獻(xiàn)】

相關(guān)期刊論文 前3條

1 ;流產(chǎn)或避孕藥均與心血管死亡無關(guān)[J];中國社區(qū)醫(yī)師;2012年01期

2 ;高血壓加吸煙對(duì)出血性腦卒中不良影響最明顯[J];中華高血壓雜志;2008年12期

3 ;[J];;年期

，

本文編號(hào)：1825489